<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761928</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-15-0809</org_study_id>
    <nct_id>NCT02761928</nct_id>
  </id_info>
  <brief_title>Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients</brief_title>
  <acronym>Hypermoble</acronym>
  <official_title>Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study of axial spine pain and hyperflexibility. Patients will receive physical&#xD;
      exam maneuvers (traditional straight leg raise, FABER, facet loading as well as Beighton's&#xD;
      hypermobility score) and blood / urine / saliva collection. They will also be separated into&#xD;
      pain groups based on their response to injections. A correlation between exam findings and&#xD;
      procedure group will be measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational study of patients with neck and back pain followed by a pain&#xD;
      management clinic. Patients with particular pain generators in the neck and back will be&#xD;
      defined by a positive response to one of several targeted interventional pain procedures.&#xD;
      Each patient may undergo a physical exam to determine whether they have hypermobile joints.&#xD;
      The study will thus evaluate the rate of hypermobility for each pain generator. In addition&#xD;
      blood, urine, or saliva samples may be taken for biomarkers for pain or rheumatologic&#xD;
      factors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment, lack of funding to continue&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Beighton hypermobility score</measure>
    <time_frame>Prior to injection (2 weeks prior to injection for each patient)</time_frame>
    <description>9 point standardized scale</description>
  </primary_outcome>
  <number_of_groups>10</number_of_groups>
  <enrollment type="Actual">31</enrollment>
  <condition>Low Back Pain, Mechanical</condition>
  <condition>Spinal Stenosis</condition>
  <condition>Nerve Root Disorder</condition>
  <condition>Radiculopathy, Cervical</condition>
  <condition>Benign Hypermobility Syndrome</condition>
  <arm_group>
    <arm_group_label>Epidural</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to any epidural (e.g. interlaminar/paramedian, transforaminal, caudal)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective nerve root block</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to selective nerve root block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Facet injection</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to intra-articular facet injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medial branch block</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to median branch nerve block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medial branch RFA</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to median branch nerve radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIJ injection</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to sacroiliac joint injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lateral branch block</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to lateral branch nerve block for SIJ</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Greater trochanter injection</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to greater trochanteric bursa injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Piriformis injection</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to piriformis injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trigger point injection</arm_group_label>
    <description>Positive response (&gt;50% pain relief) to trigger point injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Beighton score for hypermobility</intervention_name>
    <description>The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.</description>
    <arm_group_label>Epidural</arm_group_label>
    <arm_group_label>Facet injection</arm_group_label>
    <arm_group_label>Greater trochanter injection</arm_group_label>
    <arm_group_label>Lateral branch block</arm_group_label>
    <arm_group_label>Medial branch RFA</arm_group_label>
    <arm_group_label>Medial branch block</arm_group_label>
    <arm_group_label>Piriformis injection</arm_group_label>
    <arm_group_label>SIJ injection</arm_group_label>
    <arm_group_label>Selective nerve root block</arm_group_label>
    <arm_group_label>Trigger point injection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with low back pain who are determined to be candidates for a pain procedure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of axial back pain (neck, mid-back, lower back) or pain radiating&#xD;
             to the extremity, with suspected diagnosis of a specific pain generator amenable to a&#xD;
             pain procedure, including disorders of the nerves, joints, and muscles as listed&#xD;
             immediately below.&#xD;
&#xD;
          -  Clinical decision to schedule patient for a pain procedure, including procedures&#xD;
             targeting the following disorders:&#xD;
&#xD;
               -  Facet arthropathy: intra-articular facet joint injection, medial branch block,&#xD;
                  medial branch radiofrequency ablation&#xD;
&#xD;
               -  Sacroiliac joint dysfunction: sacroiliac joint injection, lateral branch block,&#xD;
                  lateral branch radiofrequency ablation&#xD;
&#xD;
               -  Myofascial pain syndrome: trigger point injection&#xD;
&#xD;
               -  Radiculopathy, spinal stenosis, or herniated nucleus pulposus: epidural steroid&#xD;
                  injection, selective nerve root block&#xD;
&#xD;
               -  Piriformis syndrome: piriformis injection&#xD;
&#xD;
               -  Greater trochanteric bursitis: greater trochanteric bursa injection&#xD;
&#xD;
          -  Able to provide HIPAA authorization to share prior medical records/imaging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous diagnosis of cancer.&#xD;
&#xD;
          -  Currently pregnant.&#xD;
&#xD;
          -  Previously enrolled for the same procedure or the same pain generator site. (For&#xD;
             example, this would exclude a patient who had an intra-articular facet joint injection&#xD;
             at the right L5/S1 if: 1) he had the same injection 3 months ago and was enrolled at&#xD;
             that time, or 2) the patient was already enrolled for a medial branch block at the&#xD;
             right L5 and sacral ala, as this targets the same facet joint.)&#xD;
&#xD;
          -  Inability or unwillingness of subject or legal guardian/representative to give&#xD;
             informed consent (e.g., ward of the state)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Burish, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grahame R. Joint hypermobility syndrome pain. Curr Pain Headache Rep. 2009 Dec;13(6):427-33. Review.</citation>
    <PMID>19889283</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Mark J Burish</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Facet Joint</keyword>
  <keyword>Sacroiliac Joint</keyword>
  <keyword>Myofascial Trigger Point Pain</keyword>
  <keyword>Injectables</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Radiculopathy</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

